Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features

Author:

Flanagan Dustin J.ORCID,Amirkhah RahelehORCID,Vincent David F.,Gunduz Nuray,Gentaz Pauline,Cammareri Patrizia,McCooey Aoife J.,McCorry Amy M. B.,Fisher Natalie C.,Davis Hayley L.ORCID,Ridgway Rachel A.ORCID,Lohuis Jeroen,Leach Joshua D. G.,Jackstadt Rene,Gilroy Kathryn,Mariella Elisa,Nixon ColinORCID,Clark William,Hedley AnnORCID,Markert Elke K.,Strathdee DouglasORCID,Bartholin LaurentORCID,Redmond Keara L.,Kerr Emma M.ORCID,Longley Daniel B.,Ginty Fiona,Cho Sanghee,Coleman Helen G.,Loughrey Maurice B.,Bardelli AlbertoORCID,Maughan Timothy S.,Campbell Andrew D.ORCID,Lawler Mark,Leedham Simon J.,Barry Simon T.ORCID,Inman Gareth J.ORCID,van Rheenen JaccoORCID,Dunne Philip D.ORCID,Sansom Owen J.ORCID

Abstract

AbstractThe pro-tumourigenic role of epithelial TGFβ signalling in colorectal cancer (CRC) is controversial. Here, we identify a cohort of born to be bad early-stage (T1) colorectal tumours, with aggressive features and a propensity to disseminate early, that are characterised by high epithelial cell-intrinsic TGFβ signalling. In the presence of concurrent Apc and Kras mutations, activation of epithelial TGFβ signalling rampantly accelerates tumourigenesis and share transcriptional signatures with those of the born to be bad T1 human tumours and predicts recurrence in stage II CRC. Mechanistically, epithelial TGFβ signalling induces a growth-promoting EGFR-signalling module that synergises with mutant APC and KRAS to drive MAPK signalling that re-sensitise tumour cells to MEK and/or EGFR inhibitors. Together, we identify epithelial TGFβ signalling both as a determinant of early dissemination and a potential therapeutic vulnerability of CRC’s with born to be bad traits.

Funder

Cancer Research UK

RCUK | Medical Research Council

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3